Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

hich may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2009, and statements regarding our clinical development programs, the effectiveness of our Vancocin and Cinryze sales efforts, our estimates of future tax rates, or our ability to execute a successful launch of Cinryze, our ability to conduct future studies with maribavir, and the timing and potential outcomes of the review of our regulatory submission related to an acute treatment indication for Cinryze.

Our 2009 revenue guidance is based upon our plans to remain vigorous in our opposition to any bioequivalence approach considered for use in approving generic formulations of Vancocin that does not require rigorous scientific methods to demonstrate safety and efficacy consistent with good medicine and science. There can be no assurance that the FDA will agree with the positions stated in our Vancocin related submissions or that our efforts to oppose the FDA's December 2008 bioequivalence guidance for Vancocin will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either our citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the recommendation set forth by the FDA in December 2008, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancoci
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... Available spectra is similar for ... and cultivation of a wide range of plants. ... with proven patented and pending wide spectrum technology. ... in critical applications in contrast to growth spectra ... customers have a large variety of differently sized ...
(Date:8/29/2014)... Electronic circuits are based on electrons, but one of ... photonic circuits, i.e. circuits based on light (photons) instead ... to create a stream of single photons and control ... sorts of attempts to achieve this control, but now ... creating a steady stream of photons emitted one at ...
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
(Date:8/28/2014)... USA (PRWEB) August 28, 2014 SPIE ... of Physics and Optical Science and Director of the ... of North Carolina at Charlotte, and co-founder and Chairman ... to serve as the 2015 Vice President of SPIE, ... 2014 President Philip Stahl announced recent election results at ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2
... Previous Quarter, NEW YORK, May 15 ... biosensor and microprocessor technologies for,use in portable monitoring ... ended March 31, 2008., Gross revenues for ... quarter 2007 gross revenues. The increase in revenues ...
... YORK, May 15 American Oriental,Bioengineering, Inc. (NYSE: ... health through the development, manufacture and commercialization,of a ... ("OTC") products in,China, today released the following statement ... with the many victims of China,s earthquake and ...
... 15 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-,Pharmaceutical Technology, Inc. ... producer of plant extracts and pharmaceutical raw ... production, today,announced that there was no damage ... the Sichuan Earthquake., Immediately following the ...
Cached Biology Technology:SPO Medical Reports First Quarter 2008 Results 2SPO Medical Reports First Quarter 2008 Results 3American Oriental Bioengineering Comments on Earthquake 2Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities 2
(Date:8/31/2014)... "electronic-nose" for sniffing the highly infectious bacteria C. ... has been developed by a team at the University ... team has demonstrated that it is possible to identify ... would lead to rapid diagnosis of the condition., What ... possible to identify different strains of the disease simply ...
(Date:8/31/2014)... Over the past several decades, malaria diagnosis has changed very ... technician smears the blood across a glass slide, stains it ... the Plasmodium parasite, which causes the disease. This approach gives ... blood an important measure of disease severity but ... , A research team from the Singapore-MIT Alliance for Research ...
(Date:8/29/2014)... University of Texas Medical Branch at Galveston has gone on ... completely protect monkeys against a lethal dose of Ebola virus ... the disease is severe. , Thomas Geisbert, professor of microbiology ... discussing advances in Ebola treatment research. The filoviruses known as ... of pathogens, with fatality rates of up to 90 percent. ...
Breaking Biology News(10 mins):Scientists develop 'electronic nose' for rapid detection of C. diff infection 2A new way to diagnose malaria 2A new way to diagnose malaria 3Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2
... first experimental evidence that birds can be deceived by camouflage ... today in Nature [3 March 2005]. , The idea that ... rapidly adopted by many armies as long ago as the ... colouration' has long been used to explain how insects such ...
... that radio-tracking could be affecting the animals they ... in the British Ecological Society's Journal of Applied ... with a "dramatic shift" in the sex ratio ... assumption that radio-tracking does not fundamentally affect the ...
... Blackburn is responsible for collecting and storing thousands of ... -- to make sure there's enough genetic material to ... deals with important livestock such as Holstein cattle and ... who is the coordinator of the animal section at ...
Cached Biology News:Radio-tracking associated with 'dramatic shift' in water vole sex ratio 2Making Sure Sacred Sheep Don't Become Extinct 2
BD Primaria 35 mm Cell Culture Dish with Easy-Grip design, surface-modified polystyrene for enhanced cell culture. (20/sp, 200/ca) Packaging: 20 / sleeve, 500 / case ...
... is a software package that provides ... for custom buffer creation, set-up of ... crystallization trials. The software helps crystallographers ... automated protein crystallography: ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
Biology Products: